Navigation Links
OGI invests in personalized medicine for age-related macular degeneration
Date:11/1/2010

Established in 2007 and based in Toronto, ArcticDx has developed a test, Macula Risk, the first of its kind and specifically designed to determine one's inherited risk for age-related macular degeneration (AMD), the most common form of acquired blindness in the developed world, affecting over 10% of individuals. ArcticDx will use the PBDF investment to undertake studies in support of a planned filing for Food and Drug Administration (FDA) approval for Macula Risk.

Macula Risk detects variations in genetic markers known to predict the progression of early asymptomatic AMD to blindness using a cheek swab sample. The eyesight of individuals who are genetically predisposed to blindness can be saved through enhanced surveillance and early treatment. Macula Risk helps target effective care to those who need it most and relieves others who would otherwise live with uncertainty.

"The investment from OGI will support our filing for FDA approval for Macula Risk," commented Mr. Gregory Hines, CEO of ArcticDx. "We think this approval is an important departure from the growing trend of direct to consumer marketing of genetic tests that have only a weak link to science and are often of no clinical value. Macula Risk stands as the best example of a validated test for a multi-genetic common human disease. Achieving FDA approval will position Macula Risk for wide spread adoption."

The Macula Risk test will be marketed to eye care professionals who manage most cases of AMD in North America. These doctors will offer the test to individuals with the dry form of the disease who have not yet lost vision.

In the industrialized world, AMD is the major cause of uncorrectable vision loss in the elderly, affecting over 2.5 million people in Canada and over 25 million people in the USA. Age‐related macular degeneration is generally a disease of the elderly with the worldwide incidence of the disease growing from one in ten people over the age of 60 to more than 1 in 4 people over the age of 75. Macular degeneration is more common than Parkinson's disease, Alzheimer's disease, breast cancer and prostate cancer combined.

"Application of genomics technologies is opening the door to an era of personalized medicine in our approach to preventing, detecting and treating human disease," commented Dr. Christian Burks, President and CEO, OGI. "We are particularly pleased to be investing in a company that grew out of applied research funded by Genome Canada through OGI."

The funded work will focus on a cohort of patient samples who had early stage AMD in the Age-Related Eye Disease Study (AREDS), a large eye survey carried out by the American National Eye Institute. These patients were followed over a five-year period to determine progression of the disease. The ArcticDx team will undertake a prospective study on this cohort to evaluate use of Macula Risk in predicting which patients will progress to wet AMD (the late form of AMD) and which will not.

OGI's PBDF program invests in opportunities based in genomics, proteomics or associated technologies that fall in the proof-of-principle (validation) phase of research and that have the short-term potential to secure a significant next step towards the marketplace. Previous recipients have included Ontario universities, research institutes and companies.


'/>"/>

Contact: Alastair Harris-Cartwright
aharriscartwright@OntarioGenomics.ca
416-673-6582
Ontario Genomics Institute
Source:Eurekalert

Related biology news :

1. OGI invests in drug discovery at InDanio Bioscience
2. JPMorgan Chase & Co., Invests $25,000 to Support Bring Me A Books San Jose Elementary School Library Initiative
3. Finland invests €1.85 million in pan-European infrastructure for biomedical research
4. University of Plymouth invests in dental research
5. NIGMS invests in scientific Grand Opportunities with Recovery Act funds
6. Texas invests record $3.5 million in startup cofounded by UTs Mauro Ferrari
7. AACR congratulates William S. Dalton on 2010 Leadership in Personalized Medicine Award
8. With growing US support for personalized medicine, a look at ethical dilemmas
9. UCSF receives $15 million to advance personalized medicine
10. Personalized approach to smoking cessation may be reality in 3-5 years
11. Pathologists call for new training program to support personalized medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2017)... April 13, 2017 UBM,s Advanced Design and ... will feature emerging and evolving technology through its 3D ... will run alongside the expo portion of the event ... and demonstrations focused on trending topics within 3D printing ... and manufacturing event will take place June 13-15, 2017 at ...
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
Breaking Biology News(10 mins):
(Date:4/21/2017)... ... April 21, 2017 , ... The impressively ... focus of researchers, engineers, product developers, and industry suppliers gathered last week for ... SPIE, the international society for optics and photonics , the event drew ...
(Date:4/21/2017)... ... , ... Frederick Innovative Technology Center, Inc. (FITCI), a business ... earned a $77,518 grant from the Rural Maryland Council (RMC) to support refurbishment ... first incubator. A non-profit corporation, FITCI is a public-private partnership of the governments ...
(Date:4/20/2017)... April 20, 2017  Eli Lilly and Company (NYSE: ... evaluating galcanezumab for the prevention of migraine at the ... take place April 22-28, 2017, in Boston ... abstracts at AAN, including safety and patient outcomes data ... with a reduction in monthly migraine headache days among ...
(Date:4/20/2017)... Kong (PRWEB) , ... April 20, 2017 , ... NetDimensions ... Global Sales. , With over 20 years of experience in the learning technologies industry, ... a sister company within Learning Technologies Group plc (LTG). At LEO, Mastin served as ...
Breaking Biology Technology: